ACADIA Pharmaceuticals Soars on Early Approval of Parkinson’s Treatment

Michael Teague |

ACADIA Pharmaceuticals (ACAD) was up 55.60 percent on Thursday, with shares trading as for as much as $12.40, after Wednesday’s closing price of $7.97.

ACADIA makes drugs that treat neurological and central nervous system-related disorders. Currently, the company is developing pimavanserin for the treatment of Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia.



The $934.86 million market-cap company’s performance was sparked by the announcement that its pimavanserin Parkinson’s disease psychosis treatment qualifies for the filing of a New Drug Application (NDA) without requiring the customary final-phase trial that was scheduled to commence later in the month.

For as many as 40 percent of those with advanced-stage Parkinson’s disease, psychosis is a commonly experienced complication, often in the form of visual hallucinations. Furthermore, Parkinson’s-related psychosis can be induced by more or less all drugs used to treat the disease.

In a statement released earlier in the day, the company said that the Food and Drug Administration “has agreed that the data from the pivotal Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing.”

ACADIA will now have to finish up testing and studies, and plans to submit the NDA request by the end of 2014.

Company CEO Dr. Uli Hacksell was quoted in the company’s statement as being happy with the FDA’s decision, saying that it “will reduce substantially both the time and cost of our PDP development program.”

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
ACAD ACADIA Pharmaceuticals Inc. 31.08 0.05 0.16 909,596 Trade
WAG26 Walgreens Boots Alliance Inc 2.125% Eur Nt Due 202 n/a n/a n/a 0 Trade

Comments

Emerging Growth

Viking Energy Group Inc

Viking Investments Group Inc provides professional advisory and consulting services to companies undergoing or anticipating periods of rapid growth, change or ownership transition.

Private Markets

Mesa-Marshall 2 Well Project

MESA Resources ("MESA") is sponsoring the development of the two well direct drilling project -- "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development of…

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…